Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Quince Therapeutics, Inc. (QNCX)
USD18.58
-0.71 (-3.68%)
US NASDAQ Healthcare Biotechnology
Address
601 Gateway Blvd 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Dirk Thye
Website
quincetx.com
IPO
2019-05-09
CIK 1662774 ISIN US22053A3059
Also trades on
NASDAQ Global Select · CRTX (USD)
NASDAQ Global Select · QNCX (USD)
Description
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD18.58
-0.71 (-3.68%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
231.8K
Beta
1.37
Float Shares
49.76M
Free Float %
89.4%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Hold
Price Targets & DCF
Current price
18.58
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 3 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-9.17
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-28.2% Q4'25: -167.9% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q4'25: +0.0% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+15.8% Q4'25: +15.8% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.32× Q4'25: -0.29× (vs Q4'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
17.05M
17.05M – 17.05M
|
292.37M
292.37M – 292.37M
+1,614.4% YoY
|
486.33M
486.33M – 486.33M
+66.3% YoY
|
705.84M
705.84M – 705.84M
+45.1% YoY
|
| EBITDA |
-35.98M
|
-58.07M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-36.17M
|
—
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-56.83M
est: -52.61M (-8.0%)
|
-83.98M
est: -47.34M (-77.4%)
|
-29.56M
-29.56M – -29.56M
+37.6% YoY
|
-2.33M
-2.33M – -2.33M
+92.1% YoY
|
2.49M
-33.39M – 45.91M
+206.8% YoY
|
11.90M
11.90M – 11.90M
+377.9% YoY
|
17.30M
17.30M – 17.30M
+45.5% YoY
|
| SGA |
17.58M
|
15.05M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.31
est: -1.22 (-7.7%)
|
-1.68
est: -1.09 (-53.5%)
|
-0.68
-0.68 – -0.68
+37.6% YoY
|
-0.05
-0.05 – -0.05
+92.1% YoY
|
0.14
-0.77 – 1.06
+368.5% YoY
|
0.28
0.28 – 0.28
+90.0% YoY
|
0.40
0.40 – 0.40
+45.5% YoY
|
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | David A. Lamond | 4.46M | 10.10% | 4.46M | — | 4.46M | — | IN | — | 2024-11-13 | ↗ |
| 2 | 10.75% | 2.89M | 10.75% | 1.92M | — | 1.92M | 962.5K | IN | United States of America | 2019-09-30 | ↗ |
| 3 | Chad Boeding | 2.86M | 9.71% | 176.8K | 2.86M | 176.8K | — | OO | DELAWARE | 2021-02-01 | ↗ |
| 4 | EPIQ Capital Group, LLC | 2.69M | 9.11% | — | 2.69M | — | — | IA | DELAWARE | 2021-02-01 | ↗ |
| 5 | Francesco Micheli | 2.53M | 5.89% | — | 2.53M | — | — | IN | Italy | 2023-12-15 | ↗ |
| 6 | Genextra S.p.A. | 2.53M | 5.89% | — | 2.53M | 2.53M | — | OO | Italy | 2023-12-15 | ↗ |
| 7 | Matteo Bruno Renzulli | 2.53M | 5.89% | — | 2.53M | — | — | IN | Italy | 2023-12-15 | ↗ |
| 8 | Capital Research Global Investors ** | 2.44M | 9.00% | 2.44M | — | 2.44M | — | IA | — | 2020-02-14 | ↗ |
| 9 | Bhaman (“Bhaman”) | 2.18M | 5.10% | 2.18M | — | 2.18M | — | IN | Citizen | 2024-02-12 | ↗ |
| 10 | Capital VIII (“SC VIII”) | 2.18M | 5.10% | 2.18M | — | 2.18M | — | OO | France | 2024-02-12 | ↗ |
| 11 | Papiernik (“Papiernik”) | 2.18M | 5.10% | 2.18M | — | 2.18M | — | IN | Citizen | 2024-02-12 | ↗ |
| 12 | Partners SAS, a French corporation (“SP SAS”) | 2.18M | 5.10% | 2.18M | — | 2.18M | — | OO | France | 2024-02-12 | ↗ |
| 13 | Richter (“Richter”) | 2.18M | 5.10% | 2.18M | — | 2.18M | — | IN | Citizen | 2024-02-12 | ↗ |
| 14 | Seghezzi (“Seghezzi”) | 2.18M | 5.10% | 2.18M | — | 2.18M | — | IN | Citizen | 2024-02-12 | ↗ |
| 15 | ( 13-5315170 | 2.06M | 7.00% | 254.2K | 1.80M | 254.2K | — | CO | Delaware | 2021-03-25 | ↗ |
| 16 | 1,925,165 | 1.93M | 7.17% | 1.93M | — | 1.93M | — | IN | United States of America | 2019-09-30 | ↗ |
| 17 | Braden M Leonard | 1.84M | 5.07% | 375.1K | 1.47M | 375.1K | 1.47M | IN | Delaware | 2023-07-17 | ↗ |
| 18 | EPQ LLC, CTYM PS | 1.75M | 5.93% | 1.75M | — | 1.75M | — | PN | DELAWARE | 2021-02-01 | ↗ |
| 19 | ( 82-5524518 | 1.59M | 5.40% | — | 1.59M | — | — | OO | Delaware | 2021-03-25 | ↗ |
| 20 | BML Investment Partners, L.P. | 1.47M | 4.04% | — | 1.47M | — | 1.47M | PN | Delaware | 2023-07-17 | ↗ |
| 21 | CTEPQ Partners LLC | 936.3K | 3.17% | 936.3K | — | 936.3K | — | PN | DELAWARE | 2021-02-01 | ↗ |
| 22 | (VOLUNTARY) 98-1625216 | 600.0K | 2.01% | — | 600.0K | — | — | OO | — | 2022-02-14 | ↗ |
| 23 | Pfizer Inc. 13-5315170 | 600.0K | 2.01% | — | 600.0K | — | — | CO | — | 2022-02-14 | ↗ |
| 24 | ( 81-4334429 | 215.7K | 0.70% | — | 215.7K | — | — | OO | Delaware | 2021-03-25 | ↗ |
| 25 | Takeda Pharmaceutical Company Limited | 87.3K | 2.00% | — | 87.3K | — | — | CO | United States | 2021-01-29 | ↗ |
| 26 | Takeda Pharmaceuticals U.S.A., Inc. | 87.3K | 0.30% | — | 87.3K | — | — | CO | United States | 2021-01-29 | ↗ |
| 27 | Takeda Ventures, Inc. | 87.3K | 0.30% | — | 87.3K | — | — | CO | United States | 2021-01-29 | ↗ |
| 28 | Takeda Pharmaceuticals International AG | 23.8K | 0.10% | — | 23.8K | — | — | CO | United States | 2021-01-29 | ↗ |
| 29 | 95-1411037 | 13.00 | 0.00% | — | — | — | — | IA | Delaware | 2022-07-08 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 51.9K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
6.00
Bullish
Ratio by volume
3.00
Bullish
Buys
6
Sells
1
Shares acquired
1.29M
Shares disposed
365.0K
Cash buys
—
Cash sales
—
Net activity
+924,504
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-23 | Thye Dirk | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 1,000,000 | 3.08 | 3.08M | 1,000,000 | D | ↗ |
| 2026-01-23 | Ryan Charles S. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 200,000 | 3.08 | 616.0K | 200,000 | D | ↗ |
| 2026-01-23 | Hannah Brendan | Officer | A-Award | D | Employee Stock Option (Right to Buy) | 365,000 | 3.08 | 1.12M | 365,000 | D | ↗ |
| 2026-01-02 | Senner Christopher J. | Director | A-Award | A | Director Stock Option (Right to Buy) | 21,810 | 3.00 | 65.4K | 21,810 | D | ↗ |
| 2026-01-02 | McLoughlin Margaret | Director | A-Award | A | Director Stock Option (Right to Buy) | 19,547 | 3.00 | 58.6K | 19,547 | D | ↗ |
| 2026-01-02 | Lamond David | Director | A-Award | A | Director Stock Option (Right to Buy) | 29,423 | 3.00 | 88.3K | 29,423 | D | ↗ |
| 2026-01-02 | Bray June | Director | A-Award | A | Director Stock Option (Right to Buy) | 18,724 | 3.00 | 56.2K | 18,724 | D | ↗ |
| 2025-12-26 | Benatti Luca | Director | S-Sale | D | Common Stock | 50,000 | 3.47 | 173.5K | 39,179 | D | ↗ |
| 2025-12-10 | Thye Dirk | Director / Officer | G-Gift | A | Common Shares | 739,885 | 0.00 | — | 739,885 | I | ↗ |
| 2025-12-05 | Hannah Brendan | Officer | M-Exempt | A | Common Shares | 2,271 | 0.55 | 1.2K | 336,547 | D | ↗ |
| 2025-06-18 | Thye Dirk | Director / Officer | A-Award | A | Common Shares | 150,944 | 1.20 | 181.1K | 994,885 | D | ↗ |
| 2025-06-18 | Ryan Charles S. | Officer | A-Award | A | Common Shares | 7,548 | 1.20 | 9.1K | 130,009 | D | ↗ |
| 2025-06-18 | Hannah Brendan | Officer | A-Award | A | Common Shares | 37,736 | 1.20 | 45.3K | 334,276 | D | ↗ |
| 2025-06-04 | Senner Christopher J. | Director | A-Award | A | Director Stock Option (Right to Buy) | 27,000 | 1.09 | 29.4K | 27,000 | D | ↗ |
| 2025-06-04 | RYAN UNA S | Director | A-Award | A | Director Stock Option (Right to Buy) | 27,000 | 1.09 | 29.4K | 27,000 | D | ↗ |
| 2025-06-04 | Patni Rajiv | Director | A-Award | A | Director Stock Option (Right to Buy) | 27,000 | 1.09 | 29.4K | 27,000 | D | ↗ |
| 2025-06-04 | McLoughlin Margaret | Director | A-Award | A | Director Stock Option (Right to Buy) | 27,000 | 1.09 | 29.4K | 27,000 | D | ↗ |
| 2025-06-04 | Lamond David | Director | A-Award | A | Director Stock Option (Right to Buy) | 27,000 | 1.09 | 29.4K | 27,000 | D | ↗ |
| 2025-06-04 | Bray June | Director | A-Award | A | Director Stock Option (Right to Buy) | 27,000 | 1.09 | 29.4K | 27,000 | D | ↗ |
| 2025-06-04 | Benatti Luca | Director | A-Award | A | Director Stock Option (Right to Buy) | 27,000 | 1.09 | 29.4K | 27,000 | D | ↗ |
| 2025-01-28 | Thye Dirk | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,200,000 | 1.60 | 1.92M | 1,200,000 | D | ↗ |
| 2025-01-28 | Ryan Charles S. | Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 1.60 | 480.0K | 300,000 | D | ↗ |
| 2025-01-28 | Hannah Brendan | Officer | A-Award | A | Employee Stock Option (right to buy) | 450,000 | 1.60 | 720.0K | 450,000 | D | ↗ |
| 2025-01-02 | Senner Christopher J. | Director | A-Award | A | Director Stock Option (right to buy) | 35,274 | 1.88 | 66.3K | 35,274 | D | ↗ |
| 2025-01-02 | McLoughlin Margaret | Director | A-Award | A | Director Stock Option (right to buy) | 31,613 | 1.88 | 59.4K | 31,613 | D | ↗ |
| 2025-01-02 | Lamond David | Director | A-Award | A | Director Stock Option (right to buy) | 47,587 | 1.88 | 89.5K | 47,587 | D | ↗ |
| 2025-01-02 | Bray June | Director | A-Award | A | Director Stock Option (right to buy) | 30,282 | 1.88 | 56.9K | 30,282 | D | ↗ |
| 2024-10-23 | Benatti Luca | Director | J-Other | A | Common Stock | 8,918 | 0.00 | — | 89,179 | D | ↗ |
| 2024-08-30 | Thye Dirk | Director / Officer | P-Purchase | A | Common Stock | 77,000 | 0.70 | 53.9K | 843,941 | — | ↗ |
| 2024-08-29 | Thye Dirk | Director / Officer | P-Purchase | A | Common Stock | 77,500 | 0.69 | 53.5K | 766,941 | — | ↗ |
| 2024-08-21 | Hannah Brendan | Officer | P-Purchase | A | Common Stock | 23,565 | 0.63 | 14.8K | 296,540 | — | ↗ |
| 2024-08-20 | Ryan Charles S. | Officer | P-Purchase | A | Common Stock | 48,387 | 0.65 | 31.5K | 122,461 | — | ↗ |
| 2024-08-20 | Hannah Brendan | Officer | P-Purchase | A | Common Stock | 3,424 | 0.60 | 2.1K | 265,695 | — | ↗ |
| 2024-08-19 | Hannah Brendan | Officer | P-Purchase | A | Common Stock | 2,155 | 0.58 | 1.2K | 259,771 | — | ↗ |
| 2024-06-05 | Senner Christopher J. | Director | A-Award | A | Employee Stock Option (right to buy) | 27,000 | 0.82 | 22.1K | 27,000 | — | ↗ |
| 2024-06-05 | RYAN UNA S | Director | A-Award | A | Employee Stock Option (right to buy) | 27,000 | 0.82 | 22.1K | 27,000 | — | ↗ |
| 2024-06-05 | Patni Rajiv | Director | A-Award | A | Employee Stock Option (right to buy) | 13,500 | 0.82 | 11.1K | 13,500 | — | ↗ |
| 2024-06-05 | McLoughlin Margaret | Director | A-Award | A | Employee Stock Option (right to buy) | 27,000 | 0.82 | 22.1K | 27,000 | — | ↗ |
| 2024-06-05 | Lamond David | Director | A-Award | A | Employee Stock Option (right to buy) | 27,000 | 0.82 | 22.1K | 27,000 | — | ↗ |
| 2024-06-05 | Bray June | Director | A-Award | A | Employee Stock Option (right to buy) | 27,000 | 0.82 | 22.1K | 27,000 | — | ↗ |
| 2024-06-05 | Benatti Luca | Director | A-Award | A | Employee Stock Option (right to buy) | 27,000 | 0.82 | 22.1K | 27,000 | — | ↗ |
| 2024-06-04 | Hannah Brendan | Officer | M-Exempt | A | Common Stock | 56,061 | 0.55 | 30.8K | 257,616 | — | ↗ |
| 2024-02-15 | Patni Rajiv | Director | A-Award | A | Employee Stock Option (right to buy) | 54,000 | 1.30 | 70.2K | 54,000 | — | ↗ |
| 2024-02-01 | Thye Dirk | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,500,000 | 1.31 | 1.97M | 1,500,000 | — | ↗ |
| 2024-02-01 | Ryan Charles S. | Officer | A-Award | A | Employee Stock Option (right to buy) | 145,000 | 1.31 | 190.0K | 145,000 | — | ↗ |
| 2024-02-01 | Hannah Brendan | Officer | A-Award | A | Employee Stock Option (right to buy) | 600,000 | 1.31 | 786.0K | 600,000 | — | ↗ |
| 2024-01-16 | Thye Dirk | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 90,531 | 0.55 | 49.8K | 115,860 | — | ↗ |
| 2023-12-14 | Lamond David | Director | P-Purchase | A | Common Stock | 22,627 | 1.04 | 23.5K | 2,347,545 | — | ↗ |
| 2023-12-13 | Lamond David | Director | P-Purchase | A | Common Stock | 22,627 | 1.00 | 22.6K | 2,324,918 | — | ↗ |
| 2023-12-12 | Lamond David | Director | P-Purchase | A | Common Stock | 22,327 | 1.02 | 22.8K | 2,302,291 | — | ↗ |
| 2023-12-07 | Lamond David | Director | P-Purchase | A | Common Stock | 19,123 | 1.01 | 19.3K | 2,279,664 | — | ↗ |
| 2023-12-06 | Lamond David | Director | P-Purchase | A | Common Stock | 19,123 | 1.02 | 19.5K | 2,260,541 | — | ↗ |
| 2023-12-05 | Lamond David | Director | P-Purchase | A | Common Stock | 19,123 | 1.01 | 19.3K | 2,241,418 | — | ↗ |
| 2023-12-01 | Lamond David | Director | P-Purchase | A | Common Stock | 14,378 | 0.94 | 13.5K | 2,222,295 | — | ↗ |
| 2023-11-30 | Lamond David | Director | P-Purchase | A | Common Stock | 14,378 | 0.90 | 12.9K | 2,207,917 | — | ↗ |
| 2023-11-29 | Lamond David | Director | P-Purchase | A | Common Stock | 14,378 | 0.98 | 14.1K | 2,193,539 | — | ↗ |
| 2023-10-24 | Hannah Brendan | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 0.99 | 74.3K | 75,000 | — | ↗ |
| 2023-10-23 | Janhofer Guenter | Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 0.99 | 297.0K | 300,000 | — | ↗ |
| 2023-10-23 | Benatti Luca | Director | — | D | Common Stock | 0 | 0.00 | — | 80,261 | — | ↗ |
| 2023-09-01 | Ryan Charles S. | Officer | A-Award | A | Employee Stock Option (right to buy) | 545,000 | 1.30 | 708.5K | 545,000 | — | ↗ |
| 2023-08-31 | Lamond David | Director | P-Purchase | A | Common Stock | 41,026 | 1.32 | 54.2K | 2,179,161 | — | ↗ |
| 2023-08-30 | Lamond David | Director | P-Purchase | A | Common Stock | 41,026 | 1.31 | 53.7K | 2,138,135 | — | ↗ |
| 2023-08-17 | Lamond David | Director | P-Purchase | A | Common Stock | 24,766 | 1.29 | 31.9K | 2,097,109 | — | ↗ |
| 2023-08-16 | Lamond David | Director | P-Purchase | A | Common Stock | 117,348 | 1.29 | 151.4K | 2,072,343 | — | ↗ |
| 2023-08-15 | Lamond David | Director | P-Purchase | A | Common Stock | 107,886 | 1.32 | 142.4K | 1,954,995 | — | ↗ |
| 2023-08-10 | Thye Dirk | Director / Officer | P-Purchase | A | Common Stock | 88,000 | 1.26 | 110.9K | 448,911 | — | ↗ |
| 2023-08-08 | Thye Dirk | Director / Officer | P-Purchase | A | Common Stock | 80,000 | 1.24 | 99.2K | 360,911 | — | ↗ |
| 2023-08-08 | McLoughlin Margaret | Director | P-Purchase | A | Common Stock | 8,000 | 1.23 | 9.8K | 8,000 | — | ↗ |
| 2023-08-08 | Hannah Brendan | Officer | P-Purchase | A | Common Stock | 71,762 | 1.22 | 87.5K | 201,555 | — | ↗ |
| 2023-05-24 | Senner Christopher J. | Director | A-Award | A | Stock Option (right to buy) | 27,000 | 1.58 | 42.7K | 27,000 | — | ↗ |
| 2023-05-24 | RYAN UNA S | Director | A-Award | A | Stock Option (right to buy) | 27,000 | 1.58 | 42.7K | 27,000 | — | ↗ |
| 2023-05-24 | McLoughlin Margaret | Director | A-Award | A | Stock Option (right to buy) | 27,000 | 1.58 | 42.7K | 27,000 | — | ↗ |
| 2023-05-24 | Lamond David | Director | A-Award | A | Stock Option (right to buy) | 27,000 | 1.58 | 42.7K | 27,000 | — | ↗ |
| 2023-05-24 | Bray June | Director | A-Award | A | Stock Option (right to buy) | 27,000 | 1.58 | 42.7K | 27,000 | — | ↗ |
| 2023-03-06 | Monohon Ted | Officer | S-Sale | D | Common Stock | 1,871 | 0.98 | 1.8K | 27,440 | — | ↗ |
| 2023-02-01 | Thye Dirk | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 600,000 | 0.94 | 564.0K | 600,000 | — | ↗ |
| 2023-02-01 | Smith Karen L. | Officer | A-Award | A | Employee Stock Option (right to buy) | 225,000 | 0.94 | 211.5K | 225,000 | — | ↗ |
| 2023-02-01 | Monohon Ted | Officer | A-Award | A | Employee Stock Option (right to buy) | 110,000 | 0.94 | 103.4K | 110,000 | — | ↗ |
| 2023-02-01 | Hannah Brendan | Officer | A-Award | A | Employee Stock Option (right to buy) | 225,000 | 0.94 | 211.5K | 225,000 | — | ↗ |
| 2022-12-05 | Monohon Ted | Officer | F-InKind | D | Common Stock | 1,640 | 0.72 | 1.2K | 29,311 | — | ↗ |
| 2022-09-06 | Monohon Ted | Officer | F-InKind | D | Common Stock | 1,520 | 1.64 | 2.5K | 30,951 | — | ↗ |
Executive team
Top executives
Shares Outstanding
55.68M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Karen Smith, M.D., Ph.D. Former Chief Medical Officer | 336.5K | — | 66.3K | 249.0K | — | 696.2K | 1.35M | 23.39% | ↗ |
| 2 | 2023 | Dirk Thye, M.D. Chief Executive Officer and Chief Medical Officer | 550.0K | — | — | 474.0K | 302.5K | 4.0K | 1.33M | 35.63% | ↗ |
| 3 | 2023 | Brendan Hannah Chief Business Officer, Chief Operating Officer and Chief Compliance Officer | 425.0K | — | — | 240.0K | 178.5K | 4.0K | 847.5K | 28.32% | ↗ |
| 4 | 2023 | Charles Ryan, Ph.D. | 147.8K | — | — | 588.6K | 70.0K | 11.2K | 817.6K | 72.00% | ↗ |
| 5 | 2022 | Casey C. Lynch Former President and Chief Executive Officer | 97.8K | — | — | 4.36M | — | 713.9K | 5.17M | 84.29% | ↗ |
| 6 | 2022 | Dirk Thye, M.D. Chief Executive Officer and Chief Medical Officer | 317.0K | — | — | 4.48M | 164.2K | 4.0K | 4.97M | 90.24% | ↗ |
| 7 | 2022 | Dirk Thye, M.D. Chief Executive Officer and Chief Medical Officer | 317.0K | — | — | 4.48M | 164.2K | 4.0K | 4.97M | 90.24% | ↗ |
| 8 | 2022 | Karen Smith, M.D., Ph.D. Former Chief Medical Officer | 273.7K | — | — | 3.09M | 115.2K | 4.0K | 3.49M | 88.73% | ↗ |
| 9 | 2022 | Karen Smith, M.D., Ph.D. Former Chief Medical Officer | 273.7K | — | — | 3.09M | 115.2K | 4.0K | 3.49M | 88.73% | ↗ |
| 10 | 2022 | Christopher Lowe Former Interim Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer and Treasurer | 225.9K | — | 752.5K | 1.99M | — | 432.6K | 3.40M | 80.64% | ↗ |
| 11 | 2022 | Leslie Holsinger Former Executive Vice President of Preclinical Development | 247.3K | — | 668.7K | 1.91M | — | 414.1K | 3.24M | 79.56% | ↗ |
| 12 | 2022 | Caryn McDowell Former Chief Legal and Administrative Officer | 253.5K | — | 602.0K | 1.84M | — | 417.5K | 3.11M | 78.44% | ↗ |
| 13 | 2022 | Brendan Hannah Chief Business Officer, Chief Operating Officer and Chief Compliance Officer | 244.9K | — | — | 800.9K | 103.1K | 4.0K | 1.15M | 69.47% | ↗ |
| 14 | 2022 | Brendan Hannah Chief Business Officer, Chief Operating Officer and Chief Compliance Officer | 244.9K | — | — | 800.9K | 103.1K | 4.0K | 1.15M | 69.47% | ↗ |
| 15 | 2021 | Christopher Lowe Former Interim Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer and Treasurer | 445.0K | — | — | 1.48M | 196.7K | 4.0K | 2.12M | 69.60% | ↗ |
| 16 | 2021 | Casey C. Lynch Former President and Chief Executive Officer | 575.0K | — | — | — | 308.3K | 4.0K | 887.3K | 0.00% | ↗ |
| 17 | 2021 | Caryn McDowell Former Chief Legal and Administrative Officer | 430.0K | — | — | — | 169.9K | 4.0K | 603.9K | 0.00% | ↗ |
| 18 | 2021 | Leslie Holsinger Former Executive Vice President of Preclinical Development | 430.0K | — | — | — | 169.9K | 4.0K | 603.9K | 0.00% | ↗ |
| 19 | 2020 | Casey C. Lynch President and Chief Executive Officer | 525.0K | — | — | 13.35M | 262.5K | — | 14.14M | 94.43% | ↗ |
| 20 | 2020 | Caryn McDowell Chief Legal and Administrative Officer and Corporate Secretary | 268.1K | — | — | 9.79M | 111.0K | — | 10.17M | 96.27% | ↗ |
| 21 | 2020 | Leslie Holsinger, Ph.D. Executive Vice President of Research and Development | 405.0K | — | — | 8.63M | 162.0K | — | 9.20M | 93.84% | ↗ |
| 22 | 2020 | Christopher Lowe Chief Operating Officer, Chief Financial Officer and Treasurer | 390.0K | — | — | 8.63M | 156.0K | — | 9.18M | 94.05% | ↗ |
| 23 | 2020 | Michael Detke, M.D., Ph.D. Chief Medical Officer | 410.0K | — | — | 7.63M | 164.0K | — | 8.20M | 93.00% | ↗ |
| 24 | 2019 | Michael Detke, M.D., Ph.D. Chief Medical Officer | 373.1K | — | — | 620.5K | 106.6K | — | 1.10M | 56.40% | ↗ |
| 25 | 2019 | Casey C. Lynch President and Chief Executive Officer | 415.6K | — | — | — | 144.4K | — | 560.0K | 0.00% | ↗ |
| 26 | 2019 | Christopher Lowe Chief Operating Officer, Chief Financial Officer and Treasurer | 357.3K | — | — | — | 104.6K | — | 461.9K | 0.00% | ↗ |
| 27 | 2019 | Leslie Holsinger, Ph.D. Executive Vice President of Research and Development | 353.6K | — | — | — | 89.3K | — | 442.9K | 0.00% | ↗ |
| 28 | 2018 | Casey C. Lynch President and Chief Executive Officer | 277.0K | 82.5K | — | — | — | — | 917.3K | 0.00% | ↗ |
| 29 | 2018 | Leslie Holsinger, Ph.D. Executive Vice President of Research and Development | 229.5K | 45.0K | — | — | — | — | 413.3K | 0.00% | ↗ |
| 30 | 2018 | Michael Detke, M.D., Ph.D. Chief Medical Officer | 6.7K | 40.0K | — | — | — | — | 239.3K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dirk Thye | Chief Executive Officer, Chief Medical Officer & Director | 767.1K | — |
| Charles S. Ryan | President | 703.1K | — |
| Brendan Hannah | Chief Business Officer, Chief Operating Officer, Chief Compliance Officer and Principal Financial & Accounting Officer | 579.9K | male |
| Mary Ellen Sillivos | Vice President of Human Resources | — | female |
| Pamela Williamson | Head of Regulatory Affairs | — | female |
| Stacy Roughan | Vice President of Corporate Communications & Investor Relations | — | female |
| Stewart A. Low | Head of Discovery | — | — |
| Giovanni Mambrini | Chief Technology Officer | — | male |
| Guenter R. Janhofer | Chief Scientific Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for QNCX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
